Materiality Navigator — Healthcare Equipment and Supplies

Environment
Industry baseline
Strong industry signal
Double materiality
Cross-cutting

Workcard generated from the catalogue

What this topic covers

Control of ethylene oxide emissions and exposure from validated sterilisation operations, including abatement, monitoring, aeration, residual management, community engagement and transition to lower-emission sterilisation technologies where validated.

How it shows up in this industry

Heat- or radiation-sensitive medical devices such as tubing sets, catheters, wound-care products and sterile polymer packs may require ethylene oxide chambers and aeration rooms under validated sterilisation controls. Scrutiny of emissions near sterilisation facilities can constrain capacity, require abatement investment and trigger revalidation of gamma, electron-beam, steam or hydrogen peroxide plasma alternatives.

Why it may be material

Ethylene oxide is highly material where used in owned or contracted sterilisation because sterilisation is a release gate for sterile devices and emission restrictions can delay shipments. The issue combines toxic air emissions, worker exposure, community concern, permitting, litigation, insurance and sterilisation capacity risk.

Impact pathway

Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach affected communities.
Potential effects may reach the atmosphere.
Potential effects may reach emergency responders.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Contractors, Customers / end-users, Employees.
The source places the pathway in Own operations, Upstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on workers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Community engagement, grievance and impact records
Emissions, air-quality and atmospheric-impact records linked to the topic
Emergency-response plans, incident logs and responder feedback
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Funding terms, lender or investor requirements and cost-of-capital analysis
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Ethylene oxide, gamma, electron-beam or steam sterilisation capacity, including validated sterilisation chambers and aeration rooms
Process-map item (emerging_pressures): Tighter scrutiny of ethylene oxide emissions and community exposure near sterilisation facilities, driving abatement investment and sterilisation redesign
Process-map item (emerging_pressures): Investor and customer demand for Scope 3 carbon data by product category, including sterilisation, freight mode, packaging and end-of-life treatment
Process-map item (external_impacts): Greenhouse gas emissions from electricity, heat, cleanroom air handling, sterilisation, resin production, metals processing and global freight
Process-map item (external_impacts): Ethylene oxide releases from sterilisation and aeration, with potential cancer risk concerns for workers and neighbouring communities

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Contractors
Customers / end-users
Employees

Users of the information

Investors / creditors
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS ESRS E2 Pollution; air pollution and substances of concernsearch disclosure cards
GRI GRI 305 Emissionssearch disclosure cards
GRI GRI 403 Occupational Health and Safetysearch disclosure cards
GRI GRI 413 Local Communities where exposure is materialsearch disclosure cards
SASB sterilisation-related environmental management may require sector-specific interpretation

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Greenhouse gas emissions reduction, energy management and product carbon evidence across cleanroom manufacturing, sterilisation, utilities, purchased materials, packaging, freight and product end-of-life assumptions.

How it shows up in this industry

ISO 7 and ISO 8 cleanrooms, HVAC, compressed air, clean steam, polymer processing, CNC machining, electronics assembly, sterilisation routes, sterile packaging and global freight contribute to device climate footprints. Hospitals and procurement organisations increasingly request product-level carbon data covering materials, sterilisation, freight mode, packaging and end-of-life assumptions for sterile disposables and capital equipment.

Why it may be material

Climate transition and product carbon performance are material because cleanroom utilities drive operating cost, Scope 3 emissions are significant in resins, metals, electronics, packaging and logistics, and hospital sustainable procurement increasingly affects tender eligibility and pricing. Unsupported product carbon claims can also damage trust.

Impact pathway

Potential effects may reach the atmosphere.
Potential effects may reach future generations.
Potential effects may reach affected communities.
Potential effects may reach ecosystems.
Affected stakeholder groups identified in the source include Customers / end-users, Suppliers.
The source places the pathway in Own operations, Upstream, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What evidence shows that customer demand is changing?

Evidence to collect

Emissions, air-quality and atmospheric-impact records linked to the topic
Long-term scenario, cumulative-impact and intergenerational analysis
Community engagement, grievance and impact records
Biodiversity, habitat and ecosystem-impact evidence
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Funding terms, lender or investor requirements and cost-of-capital analysis
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Electronics assembly areas for printed circuit boards, sensors, embedded software loading and device calibration
Process-map item (assets): Ethylene oxide, gamma, electron-beam or steam sterilisation capacity, including validated sterilisation chambers and aeration rooms
Process-map item (assets): Warehouses for quarantined, released, recalled and temperature-controlled medical stock, with lot and serial traceability systems
Process-map item (customers): Public health services, defence medical services and disaster-response agencies
Process-map item (customers): Medical distributors, wholesalers, logistics providers and pharmacy chains

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.

Affected stakeholders

Customers / end-users
Suppliers

Users of the information

Board / management
Investors / creditors
NGOs / civil society
Regulators

Standards to check

ESRS ESRS E1 Climate change; energy consumption, Scope 1, Scope 2 and Scope 3 emissionssearch disclosure cards
GRI GRI 302 Energysearch disclosure cards
GRI GRI 305 Emissionssearch disclosure cards
SASB energy management and lifecycle emissions may require industry-specific metric selection

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Lifecycle responsibility for medical devices and sterile packaging after sale, including lower material use, reusable or refurbishable models, take-back, battery returns, waste electrical equipment interfaces and recovery options compatible with infection-control requirements.

How it shows up in this industry

The industry produces sterile single-use consumables, trays, drapes, tubing, wound dressings, sample collection products and sterile barrier packaging that often enter contaminated clinical waste streams and are incinerated. It also supplies reusable instruments, loaner kits, capital equipment, batteries and electronics requiring refurbishment, decommissioning, WEEE or battery return interfaces and lot-traceable reverse logistics.

Why it may be material

Circularity is increasingly material because hospital procurement scores waste, packaging, product carbon and take-back options, while waste electrical equipment and battery obligations affect downstream responsibilities. Redesigning sterile packs and qualifying reusable alternatives can require investment but may protect revenue and reduce hospital waste burdens.

Impact pathway

Potential effects may reach downstream users.
Potential effects may reach consumers.
Potential effects may reach affected communities.
Potential effects may reach ecosystems.
Potential effects may reach water bodies.
Potential effects may reach soil and groundwater.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Affected communities, Customers / end-users, Suppliers.
The source places the pathway in Downstream, Own operations, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which products, services, customers or end uses create or concentrate the pathway?
Which own operations, assets or decisions create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on downstream users?
What evidence shows that customer demand is changing?

Evidence to collect

Downstream-user outcome, complaint and product-use evidence
Consumer outcome, complaint and product-impact records
Community engagement, grievance and impact records
Biodiversity, habitat and ecosystem-impact evidence
Water withdrawal, discharge, quality and catchment-impact records
Soil and groundwater monitoring, incident and remediation records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): ISO 7 and ISO 8 cleanrooms for component moulding, assembly and final packing of sterile devices
Process-map item (assets): Electronics assembly areas for printed circuit boards, sensors, embedded software loading and device calibration
Process-map item (assets): Warehouses for quarantined, released, recalled and temperature-controlled medical stock, with lot and serial traceability systems
Process-map item (assets): Quality management systems, design history files, technical files, clinical evaluation reports, UDI databases, patents and regulatory licences
Process-map item (customers): Public health services, defence medical services and disaster-response agencies

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Affected communities
Customers / end-users
Suppliers

Users of the information

Investors / creditors
NGOs / civil society
Regulators

Standards to check

ESRS ESRS E5 Resource use and circular economysearch disclosure cards
GRI GRI 306 Waste and product-related waste impactssearch disclosure cards
SASB product lifecycle management and packaging-related issues may require sector-specific interpretation

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Controlled segregation, storage, treatment, recycling and disposal of hazardous and non-hazardous manufacturing residues from medical device production, laboratories, sterilisation support and maintenance.

How it shows up in this industry

Production of medical equipment and supplies generates polymer sprues, rejected sterile lots, expired products, metal swarf, used filters, contaminated wipes, off-specification electronics, microbiological testing residues and maintenance wastes. Some streams require controlled disposal because they contain solvents, acids, bioburden media, metals, batteries or contaminated device residues.

Why it may be material

Hazardous and production waste is material where poor segregation, contractor oversight or disposal practices allow hazardous constituents to affect workers, waste handlers, water bodies or soils. Rejected sterile lots and off-specification components can also signal process inefficiency and raise disposal cost.

Impact pathway

Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach ecosystems.
Potential effects may reach water bodies.
Potential effects may reach soil and groundwater.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Affected communities, Contractors, Employees, Suppliers.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on workers?
What is the scale, scope, likelihood and remediability of effects on contractors?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Biodiversity, habitat and ecosystem-impact evidence
Water withdrawal, discharge, quality and catchment-impact records
Soil and groundwater monitoring, incident and remediation records
Community engagement, grievance and impact records
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): ISO 7 and ISO 8 cleanrooms for component moulding, assembly and final packing of sterile devices
Process-map item (assets): Injection moulding, extrusion, thermoforming and blow-moulding lines for polymer disposables and tubing
Process-map item (assets): CNC machining, laser cutting, welding, passivation and surface-finishing equipment for stainless steel, titanium and cobalt-chromium components
Process-map item (assets): Warehouses for quarantined, released, recalled and temperature-controlled medical stock, with lot and serial traceability systems
Process-map item (customers): Original equipment manufacturers buying components, subassemblies, sensors, tubing, sterile packs or contract-manufactured devices

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities
Contractors
Employees
Suppliers

Users of the information

NGOs / civil society
Regulators

Standards to check

ESRS ESRS E5 Resource use and circular economysearch disclosure cards
ESRS ESRS E2 Pollution; hazardous waste managementsearch disclosure cards
GRI GRI 306 Wastesearch disclosure cards
SASB Operational environmental management for manufacturing waste where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Water withdrawal, treatment and discharge quality for medical device manufacturing and testing operations, especially metal finishing, passivation, cleaning, coating, microbiology and equipment maintenance processes.

How it shows up in this industry

Device manufacturing sites may use purified water, clean steam, detergents, passivation acids, polishing compounds, coating chemistries, microbiological testing media and cleaning chemicals. Metal finishing, passivation, laboratory testing, cleaning validation and equipment maintenance can generate wastewater requiring treatment before discharge.

Why it may be material

Water and effluent materiality varies by site mix, with stronger relevance for metal instruments, implants, coatings, microbiology laboratories and cleaning-intensive operations. Poor discharge controls can affect local water quality and create permit penalties, treatment CAPEX and site expansion challenges.

Impact pathway

Potential effects may reach water bodies.
Potential effects may reach soil and groundwater.
Potential effects may reach ecosystems.
Potential effects may reach affected communities.
Affected stakeholder groups identified in the source include Affected communities.
The source places the pathway in Own operations.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on water bodies?
What is the scale, scope, likelihood and remediability of effects on soil and groundwater?
What is the scale, scope, likelihood and remediability of effects on ecosystems?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Water withdrawal, discharge, quality and catchment-impact records
Soil and groundwater monitoring, incident and remediation records
Biodiversity, habitat and ecosystem-impact evidence
Community engagement, grievance and impact records
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Process-map item (assets): CNC machining, laser cutting, welding, passivation and surface-finishing equipment for stainless steel, titanium and cobalt-chromium components
Process-map item (assets): Quality management systems, design history files, technical files, clinical evaluation reports, UDI databases, patents and regulatory licences
Process-map item (external_impacts): Volatile organic compound emissions from solvent cleaning, adhesives, coatings, inks and surface preparation
Process-map item (external_impacts): Wastewater containing detergents, passivation acids, metal residues, polishing compounds, bioburden testing media and cleaning chemicals
Process-map item (financial_channels): Operating costs for quality systems, post-market surveillance, clinical follow-up, supplier audits, sterile packaging, calibration and field service

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.

Affected stakeholders

Affected communities

Users of the information

Board / management
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS ESRS E3 Water and marine resourcessearch disclosure cards
ESRS ESRS E2 Pollution of watersearch disclosure cards
GRI GRI 303 Water and Effluentssearch disclosure cards
SASB No highly specific medical equipment anchor; may be addressed through operational environmental management

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Business-model dependent
Moderate industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Prevention and control of routine air emissions from medical device manufacturing processes, including solvent cleaning, adhesive bonding, coatings, inks, disinfection, machining, welding, laser cutting and combustion utilities.

How it shows up in this industry

Medical device production can involve isopropyl alcohol, solvents, adhesives, coatings, lubricants, inks, disinfectants, laser cutting, welding, polishing, passivation and combustion utilities. These processes can release volatile organic compounds, particulates, metal fumes and combustion gases from cleanroom and non-cleanroom areas, especially in coating, bonding, printing and metal component operations.

Why it may be material

Routine manufacturing air emissions are material where coating, bonding, cleaning, welding, laser processing or surface finishing are significant. Controls can affect permits, ventilation CAPEX, solvent substitution costs, worker comfort and community acceptance around manufacturing sites.

Impact pathway

Potential effects may reach workers.
Potential effects may reach affected communities.
Potential effects may reach the atmosphere.
Potential effects may reach ecosystems.
Affected stakeholder groups identified in the source include Affected communities, Contractors, Employees.
The source places the pathway in Own operations.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on workers?
What is the scale, scope, likelihood and remediability of effects on affected communities?
What is the scale, scope, likelihood and remediability of effects on the atmosphere?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Workforce, health and safety, engagement and grievance records
Community engagement, grievance and impact records
Emissions, air-quality and atmospheric-impact records linked to the topic
Biodiversity, habitat and ecosystem-impact evidence
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): CNC machining, laser cutting, welding, passivation and surface-finishing equipment for stainless steel, titanium and cobalt-chromium components
Process-map item (emerging_pressures): Tighter scrutiny of ethylene oxide emissions and community exposure near sterilisation facilities, driving abatement investment and sterilisation redesign
Process-map item (emerging_pressures): Adoption of additive manufacturing and patient-specific devices creating new validation, powder handling, traceability and intellectual property risks
Process-map item (external_impacts): Greenhouse gas emissions from electricity, heat, cleanroom air handling, sterilisation, resin production, metals processing and global freight
Process-map item (external_impacts): Volatile organic compound emissions from solvent cleaning, adhesives, coatings, inks and surface preparation

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.

Affected stakeholders

Affected communities
Contractors
Employees

Users of the information

Board / management
Local authorities
Regulators

Standards to check

ESRS ESRS E2 Pollution; air pollutionsearch disclosure cards
GRI GRI 305 Emissions for significant air emissionssearch disclosure cards
SASB Operational environmental management for manufacturing emissions where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Environment
Business-model dependent
Entity-specific validation required
Double materiality
Cross-cutting

Workcard generated from the catalogue

What this topic covers

Prevention, response and remediation for unintended environmental releases from chemicals, sterilants, batteries, contaminated returns and industrial storage areas at medical device manufacturing, sterilisation, warehousing and service locations.

How it shows up in this industry

Medical device sites and depots store solvents, passivation acids, disinfectants, ethylene oxide, batteries, metalworking fluids, cleaning chemicals and contaminated returns. Manufacturing, sterilisation, warehousing and maintenance activities can create spill pathways to drains, soils or groundwater, particularly where older sites, chemical stores or contractor-managed waste areas lack robust containment.

Why it may be material

Environmental release and contamination is material where hazardous chemicals, batteries, sterilants or legacy industrial sites are present. Even infrequent incidents can create remediation liabilities, insurance claims, enforcement, community concern and operational restrictions.

Impact pathway

Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach affected communities.
Potential effects may reach water bodies.
Potential effects may reach soil and groundwater.
Potential effects may reach ecosystems.
Potential effects may reach emergency responders.
Affected stakeholder groups identified in the source include Affected communities, Contractors, Employees.
The source places the pathway in Own operations, Cross value chain.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on workers?
What is the scale, scope, likelihood and remediability of effects on contractors?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Community engagement, grievance and impact records
Water withdrawal, discharge, quality and catchment-impact records
Soil and groundwater monitoring, incident and remediation records
Biodiversity, habitat and ecosystem-impact evidence
Emergency-response plans, incident logs and responder feedback
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (external_impacts): Ethylene oxide releases from sterilisation and aeration, with potential cancer risk concerns for workers and neighbouring communities
Process-map item (external_impacts): Potential contamination and exposure from batteries, flame retardants, heavy metals, PFAS coatings, phthalates and antimicrobial additives
Process-map item (impact_channels): Local water bodies and soils affected by wastewater, accidental chemical releases, landfill leachate or poorly controlled waste disposal
Process-map item (inputs): Batteries and energy storage components, especially lithium-ion, alkaline and button cells for portable and implant-adjacent devices
Process-map item (logistics): Clean, segregated transport of components to prevent particulate, moisture, electrostatic discharge or bioburden contamination before assembly

It may be less material when…

Entity-specific evidence does not show meaningful scale, exposure or effects.
The relevant business model, activity, asset or product is not present or is not significant.

Affected stakeholders

Affected communities
Contractors
Employees

Users of the information

Board / management
Investors / creditors
Local authorities
Regulators

Standards to check

ESRS ESRS E2 Pollution; pollution of soil, water and incidentssearch disclosure cards
GRI GRI 306 Wastesearch disclosure cards
GRI GRI 303 Water and Effluents where releases affect waste and water pathwayssearch disclosure cards
SASB Operational environmental management and liabilities where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Management of patient and clinician safety through device design, verification, validation, sterility, usability, labelling, real-world performance monitoring, complaint handling and corrective action across medical equipment and supplies.

How it shows up in this industry

Medical equipment and supplies manufacturers rely on ISO 13485 quality systems, ISO 14971 risk management, design history files, clinical evaluation reports, UDI records, validated cleanroom assembly, ISO 11607 sterile packaging, sterilisation validation, calibration and batch release controls for sterile consumables, implants, reusable instruments, monitoring equipment, home-care devices and wearables.

Why it may be material

Product safety, sterility and post-market quality are core because device approvals, hospital tenders and patient outcomes depend on safe design, clinical performance, validated sterility, traceability and timely corrective action. Failures can cause patient harm, recalls, warning letters, litigation, insurance escalation and loss of hospital procurement eligibility.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach workers.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Workforce, health and safety, engagement and grievance records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): ISO 7 and ISO 8 cleanrooms for component moulding, assembly and final packing of sterile devices
Process-map item (assets): Electronics assembly areas for printed circuit boards, sensors, embedded software loading and device calibration
Process-map item (assets): Microbiology, biocompatibility, mechanical fatigue, electrical safety and metrology laboratories
Process-map item (assets): Warehouses for quarantined, released, recalled and temperature-controlled medical stock, with lot and serial traceability systems
Process-map item (assets): Quality management systems, design history files, technical files, clinical evaluation reports, UDI databases, patents and regulatory licences

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Business partners
Customers / end-users

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS S4 Consumers and end-users; health and safety impacts and product responsibilitysearch disclosure cards
GRI GRI 416 Customer Health and Safetysearch disclosure cards
SASB product safety, recalls, adverse events and regulatory quality matters

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Management of restricted and hazardous substances in device materials, coatings, adhesives, batteries, electronics and packaging, including substitution, biocompatibility evidence, supplier declarations and regulatory revalidation.

How it shows up in this industry

Medical devices use PVC, polyurethane, silicone, PTFE, polycarbonate, ABS, coatings, adhesives, lubricants, membranes, batteries and electronics in patient-contact and support functions. Restrictions under REACH, RoHS, battery rules and customer lists can affect tubing, catheters, membranes, sensor housings, sterile packaging and accessories, requiring ISO 10993 biological evaluation, supplier change control and regulatory revalidation.

Why it may be material

Substance restrictions and biocompatibility chemistry are material because material changes often require design verification, extractables and leachables evidence, shelf-life testing, sterile barrier validation, technical file updates and customer requalification. Poor control can lead to patient exposure claims, product bans, recalls, tender exclusion and stranded inventories.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach workers.
Potential effects may reach ecosystems.
Potential effects may reach water bodies.
Potential effects may reach soil and groundwater.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Customers / end-users, Suppliers.
The source places the pathway in Own operations, Upstream, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Workforce, health and safety, engagement and grievance records
Biodiversity, habitat and ecosystem-impact evidence
Water withdrawal, discharge, quality and catchment-impact records
Soil and groundwater monitoring, incident and remediation records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): ISO 7 and ISO 8 cleanrooms for component moulding, assembly and final packing of sterile devices
Process-map item (assets): Injection moulding, extrusion, thermoforming and blow-moulding lines for polymer disposables and tubing
Process-map item (assets): CNC machining, laser cutting, welding, passivation and surface-finishing equipment for stainless steel, titanium and cobalt-chromium components
Process-map item (assets): Electronics assembly areas for printed circuit boards, sensors, embedded software loading and device calibration
Process-map item (assets): Microbiology, biocompatibility, mechanical fatigue, electrical safety and metrology laboratories

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Customers / end-users
Suppliers

Users of the information

Board / management
Investors / creditors
NGOs / civil society
Regulators

Standards to check

ESRS ESRS E2 Pollution; substances of concern and substances of very high concernsearch disclosure cards
GRI GRI 416 Customer Health and Safetysearch disclosure cards
GRI GRI 417 Marketing and Labelling where material content and safe-use information affect userssearch disclosure cards
SASB product safety and product design considerations for restricted substances

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Protection of employees and contractors from health and safety hazards in precision manufacturing, cleanroom assembly, laboratories, sterilisation support, warehousing, field service, refurbishment and maintenance of medical devices.

How it shows up in this industry

Workers in medical equipment and supplies operations handle precision machining, laser cutting, welding, passivation acids, surface finishing, polymer moulding, cleanroom assembly, adhesives, inks, disinfectants, microbiology testing, calibration, warehouse handling and field service. They may face solvent exposure, laser fumes, metalworking fluids, repetitive tasks, sharp components, lithium battery handling and sterilant interfaces.

Why it may be material

Worker health and safety is core because the hazards arise directly from regulated device manufacturing and service processes. Injuries and exposure exceedances can disrupt validated production, increase insurance and compensation costs, trigger enforcement, and require investment in guarding, ventilation, automation and ergonomic redesign.

Impact pathway

Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach emergency responders.
Affected stakeholder groups identified in the source include Contractors, Employees, Trade unions.
The source places the pathway in Own operations.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on workers?
What is the scale, scope, likelihood and remediability of effects on contractors?
What is the scale, scope, likelihood and remediability of effects on emergency responders?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Emergency-response plans, incident logs and responder feedback
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): CNC machining, laser cutting, welding, passivation and surface-finishing equipment for stainless steel, titanium and cobalt-chromium components
Process-map item (assets): Ethylene oxide, gamma, electron-beam or steam sterilisation capacity, including validated sterilisation chambers and aeration rooms
Process-map item (assets): Microbiology, biocompatibility, mechanical fatigue, electrical safety and metrology laboratories
Process-map item (assets): Warehouses for quarantined, released, recalled and temperature-controlled medical stock, with lot and serial traceability systems
Process-map item (assets): Field service depots, calibration tools and spare-parts inventories for installed hospital equipment

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.

Affected stakeholders

Contractors
Employees
Trade unions

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS S1 Own workforce; health and safetysearch disclosure cards
GRI GRI 403 Occupational Health and Safetysearch disclosure cards
SASB employee health and safety metrics where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Business-model dependent
Moderate industry signal
Double materiality
Cross-cutting

Workcard generated from the catalogue

What this topic covers

Safety and emergency controls for dangerous-goods transport and storage in medical device supply chains, including ethylene oxide, solvents, acids, lithium batteries, disinfectants and contaminated returns.

How it shows up in this industry

Medical device supply chains move ethylene oxide cylinders, solvents, passivation acids, disinfectants, lithium batteries and temperature- or humidity-sensitive components between manufacturing sites, sterilisation providers, quarantine warehouses, distribution centres and field service locations. Incorrect classification, packaging, storage or loading can expose drivers, warehouse workers, emergency responders and communities along freight routes.

Why it may be material

Hazardous logistics is material because dangerous goods are integral to sterilisation, cleaning, passivation, maintenance, batteries and returns. The issue is coherent across worker and public safety, environmental release prevention, governance controls, shipment continuity and liability exposure.

Impact pathway

Potential effects may reach workers.
Potential effects may reach contractors.
Potential effects may reach affected communities.
Potential effects may reach emergency responders.
Potential effects may reach soil and groundwater.
Potential effects may reach water bodies.
Potential effects may reach the atmosphere.
Affected stakeholder groups identified in the source include Affected communities, Business partners, Contractors, Customers / end-users, Employees.
The source places the pathway in Upstream, Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Workforce, health and safety, engagement and grievance records
Contractor working-condition, incident and engagement records
Community engagement, grievance and impact records
Emergency-response plans, incident logs and responder feedback
Soil and groundwater monitoring, incident and remediation records
Water withdrawal, discharge, quality and catchment-impact records
Emissions, air-quality and atmospheric-impact records linked to the topic
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Ethylene oxide, gamma, electron-beam or steam sterilisation capacity, including validated sterilisation chambers and aeration rooms
Process-map item (assets): Microbiology, biocompatibility, mechanical fatigue, electrical safety and metrology laboratories
Process-map item (customers): Hospitals, surgical centres and emergency departments purchasing through tenders and group procurement organisations
Process-map item (customers): Medical distributors, wholesalers, logistics providers and pharmacy chains
Process-map item (emerging_pressures): Tighter scrutiny of ethylene oxide emissions and community exposure near sterilisation facilities, driving abatement investment and sterilisation redesign

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.

Affected stakeholders

Affected communities
Business partners
Contractors
Customers / end-users
Employees

Users of the information

Local authorities
Regulators

Standards to check

ESRS ESRS S1 Own workforcesearch disclosure cards
ESRS ESRS S3 Affected communitiessearch disclosure cards
ESRS ESRS E2 Pollution linked to transport of hazardous substancessearch disclosure cards
GRI GRI 403 Occupational Health and Safetysearch disclosure cards
GRI GRI 306 Waste where transport incidents create significant impactssearch disclosure cards
SASB supply chain and operational safety aspects for medical equipment logistics

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Social
Business-model dependent
Entity-specific validation required
Double materiality

Workcard generated from the catalogue

What this topic covers

Management of local community amenity and trust around medical device manufacturing, sterilisation and distribution sites, including noise, traffic, odour perception, perceived safety, consultation and grievance response.

How it shows up in this industry

Manufacturing sites, sterilisation plants and distribution hubs for medical equipment can create local noise, truck traffic, odour perception, visual amenity issues and anxiety about hazardous materials or sterilisation operations. These effects are most relevant near ethylene oxide facilities, large warehouses, cleanroom manufacturing campuses and industrial clusters serving hospitals and distributors.

Why it may be material

Community amenity is material where sites are close to residential areas or expand sterilisation, warehousing or distribution capacity. Poor engagement can amplify concern about emissions, traffic and hazardous materials, affecting permitting, reputation and the social licence for site operations.

Impact pathway

Potential effects may reach affected communities.
Potential effects may reach emergency responders.
Affected stakeholder groups identified in the source include Affected communities.
The source places the pathway in Own operations, Downstream.

Financial pathway

The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on affected communities?
What is the scale, scope, likelihood and remediability of effects on emergency responders?
What civil-society scrutiny or campaigns could change the topic's relevance?

Evidence to collect

Community engagement, grievance and impact records
Emergency-response plans, incident logs and responder feedback
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Ethylene oxide, gamma, electron-beam or steam sterilisation capacity, including validated sterilisation chambers and aeration rooms
Process-map item (emerging_pressures): Tighter scrutiny of ethylene oxide emissions and community exposure near sterilisation facilities, driving abatement investment and sterilisation redesign
Process-map item (emerging_pressures): Investor and customer demand for Scope 3 carbon data by product category, including sterilisation, freight mode, packaging and end-of-life treatment
Process-map item (external_impacts): Greenhouse gas emissions from electricity, heat, cleanroom air handling, sterilisation, resin production, metals processing and global freight
Process-map item (external_impacts): Ethylene oxide releases from sterilisation and aeration, with potential cancer risk concerns for workers and neighbouring communities

It may be less material when…

Entity-specific evidence does not show meaningful scale, exposure or effects.
The relevant business model, activity, asset or product is not present or is not significant.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Affected communities

Users of the information

Board / management
Local authorities
Media
NGOs / civil society
Regulators

Standards to check

ESRS ESRS S3 Affected communitiessearch disclosure cards
GRI GRI 413 Local Communitiessearch disclosure cards
SASB No precise SASB Medical Equipment & Supplies community amenity topic; may be considered through operational context

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Financial materiality

Workcard generated from the catalogue

What this topic covers

Governance of ethical conduct and regulatory compliance across quality systems, market authorisations, public and private tenders, distributor relationships, sales practices, labelling controls, import registrations and whistleblowing channels.

How it shows up in this industry

Medical equipment and supplies companies operate under EU MDR, EU IVDR where applicable, UK Medical Devices Regulations, UKCA marking, FDA 21 CFR Part 820, FDA labelling rules, post-market reporting, ISO 13485, ISO 14971, IEC 60601, ISO 10993, ISO 11607, sterilisation standards, UDI and EUDAMED obligations. Sales through hospitals, public health services, distributors and group procurement organisations create bribery, inducement, tender integrity and distributor oversight exposures.

Why it may be material

Regulatory compliance and ethical conduct are core because market access depends on maintained quality systems, accurate technical files, valid registrations and ethical tender behaviour. Failures can produce warning letters, import restrictions, delayed approvals, fines, monitor costs, distributor terminations and loss of trust with hospitals and regulators.

Impact pathway

Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence shows current or anticipated financial effects on the organisation?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
Could this topic affect demand, pricing, market access or revenue?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Funding terms, lender or investor requirements and cost-of-capital analysis
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Electronics assembly areas for printed circuit boards, sensors, embedded software loading and device calibration
Process-map item (assets): Warehouses for quarantined, released, recalled and temperature-controlled medical stock, with lot and serial traceability systems
Process-map item (assets): Quality management systems, design history files, technical files, clinical evaluation reports, UDI databases, patents and regulatory licences
Process-map item (customers): Hospitals, surgical centres and emergency departments purchasing through tenders and group procurement organisations
Process-map item (customers): Public health services, defence medical services and disaster-response agencies

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.

Affected stakeholders

Business partners
Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS G1 Business conduct; corporate culture, corruption and bribery, protection of whistleblowers and management of relationships with supplierssearch disclosure cards
GRI GRI 205 Anti-corruptionsearch disclosure cards
GRI GRI 206 Anti-competitive Behavioursearch disclosure cards
GRI GRI 2 governance disclosuressearch disclosure cards
SASB regulatory compliance, quality management and business ethics matters where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality
Cross-cutting

Workcard generated from the catalogue

What this topic covers

Governance of cyber-security and data protection for software-enabled, connected and remotely serviced medical devices, including secure design, vulnerability management, firmware updates, hospital network interfaces and patient data controls.

How it shows up in this industry

Medical equipment increasingly includes printed circuit boards, sensors, embedded software, firmware loading, calibration, remote monitoring, software updates and hospital network connectivity. Connected infusion pumps, patient monitors, home-care devices and diagnostic equipment must operate safely on hospital and home networks while protecting patient data under GDPR-style requirements and customer cyber-security expectations.

Why it may be material

Connected-device cyber-security is material because vulnerabilities can interrupt therapy or monitoring, expose patient data, block hospital tenders, delay launches, trigger field safety corrective actions, increase cyber-insurance cost and undermine trust with hospitals and home-care users.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Potential effects may reach workers.
Potential effects may reach future generations.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Employees.
The source places the pathway in Own operations, Downstream, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect insurance availability, coverage terms, premiums or claims.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on consumers?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Workforce, health and safety, engagement and grievance records
Long-term scenario, cumulative-impact and intergenerational analysis
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Insurance coverage, premium, exclusion and claims records
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): ISO 7 and ISO 8 cleanrooms for component moulding, assembly and final packing of sterile devices
Process-map item (assets): Electronics assembly areas for printed circuit boards, sensors, embedded software loading and device calibration
Process-map item (assets): Warehouses for quarantined, released, recalled and temperature-controlled medical stock, with lot and serial traceability systems
Process-map item (customers): Public health services, defence medical services and disaster-response agencies
Process-map item (customers): Medical distributors, wholesalers, logistics providers and pharmacy chains

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant downstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Business partners
Customers / end-users
Employees

Users of the information

Board / management
Investors / creditors
Regulators

Standards to check

ESRS ESRS S4 Consumers and end-users; privacy, safety and access to quality information for userssearch disclosure cards
GRI GRI 418 Customer Privacy, with patient safety links requiring additional interpretationsearch disclosure cards
SASB data security, connected-device reliability and regulatory compliance topics where applicable

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Industry baseline
Strong industry signal
Double materiality

Workcard generated from the catalogue

What this topic covers

Due diligence and traceability for critical medical-device inputs and outsourced processes, addressing upstream labour conditions, extraction impacts, environmental controls, supplier qualification, change management, provenance and supply continuity.

How it shows up in this industry

Medical equipment supply chains rely on long-qualified resins, silicone, stainless steel, titanium, cobalt-chromium, nitinol, semiconductors, printed circuit boards, rare earth magnets, batteries, sterile packaging, contract manufacturing and contract sterilisation. Qualification cycles, change-control requirements and regulatory file implications can lock in suppliers, making continuity, provenance, labour and environmental issues hard to correct quickly.

Why it may be material

Supplier governance is material because shortages or unplanned changes in validated inputs can interrupt supply of clinically necessary devices and require revalidation, biocompatibility evidence, packaging integrity testing or regulatory submissions. Upstream extraction, electronics and contract processing also create labour, community and ecosystem impacts that affect customer trust and due diligence expectations.

Impact pathway

Potential effects may reach supply-chain workers.
Potential effects may reach affected communities.
Potential effects may reach ecosystems.
Potential effects may reach water bodies.
Potential effects may reach soil and groundwater.
Potential effects may reach Indigenous peoples.
Potential effects may reach future generations.
Potential effects may reach downstream users.
Potential effects may reach consumers.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Suppliers, Value chain workers.
The source places the pathway in Upstream, Own operations, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect asset useful lives, impairment assumptions, valuations or stranded-asset exposure.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which own operations, assets or decisions create or concentrate the pathway?
Where across the value chain is the pathway most significant?
What is the scale, scope, likelihood and remediability of effects on supply-chain workers?
What geopolitical developments could change the topic's relevance?

Evidence to collect

Supplier workforce, audit, grievance and remediation records
Community engagement, grievance and impact records
Biodiversity, habitat and ecosystem-impact evidence
Water withdrawal, discharge, quality and catchment-impact records
Soil and groundwater monitoring, incident and remediation records
Indigenous engagement, consent, grievance and impact records
Long-term scenario, cumulative-impact and intergenerational analysis
Downstream-user outcome, complaint and product-use evidence
Consumer outcome, complaint and product-impact records
Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Provision, claim, penalty, remediation and contingent-liability records
Funding terms, lender or investor requirements and cost-of-capital analysis
Asset valuations, useful-life assumptions, impairment tests and stranded-asset analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Electronics assembly areas for printed circuit boards, sensors, embedded software loading and device calibration
Process-map item (assets): Warehouses for quarantined, released, recalled and temperature-controlled medical stock, with lot and serial traceability systems
Process-map item (customers): Public health services, defence medical services and disaster-response agencies
Process-map item (customers): Medical distributors, wholesalers, logistics providers and pharmacy chains
Process-map item (customers): Original equipment manufacturers buying components, subassemblies, sensors, tubing, sterile packs or contract-manufactured devices

It may be less material when…

Organisation-specific evidence does not support significant scale, severity, likelihood or financial effect.
The organisation has no meaningful exposure to or influence over the relevant upstream pathway.
The emerging signal has not yet created a relevant exposure, impact or financial effect for the organisation.

Affected stakeholders

Business partners
Customers / end-users
Suppliers
Value chain workers

Users of the information

Investors / creditors
NGOs / civil society
Regulators

Standards to check

ESRS ESRS S2 Workers in the value chainsearch disclosure cards
ESRS ESRS G1 Business conduct and supplier relationship managementsearch disclosure cards
GRI GRI 204 Procurement Practicessearch disclosure cards
GRI GRI 308 Supplier Environmental Assessmentsearch disclosure cards
GRI GRI 414 Supplier Social Assessmentsearch disclosure cards
SASB supply chain management for critical inputs and product quality continuity

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Business-model dependent
Moderate industry signal
Financial materiality

Workcard generated from the catalogue

What this topic covers

Governance and transparency of lobbying, political contributions and trade association engagement on medical device regulation, sterilisation, chemical restrictions, sustainable procurement, reimbursement and connected-device rules.

How it shows up in this industry

Medical device manufacturers have strong interests in EU MDR and IVDR implementation, FDA quality system rules, UKCA requirements, post-market evidence expectations, UDI systems, ethylene oxide emission standards, REACH and RoHS restrictions, WEEE and battery rules, public procurement criteria and cyber-security expectations for connected devices. Policy engagement can influence timelines, technical feasibility and market access for regulated products.

Why it may be material

Public policy engagement is material because the industry is highly regulated and often participates in consultations and trade associations affecting product approval, sterilisation capacity, chemical substitution, data protection and sustainable procurement rules. Misaligned or opaque lobbying can damage trust with regulators, hospitals, investors and civil society.

Impact pathway

Affected stakeholder groups identified in the source include Business partners, Customers / end-users.
The source places the pathway in Own operations, Cross value chain.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect access to finance, funding terms or the cost of capital.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence shows current or anticipated financial effects on the organisation?
Which own operations, assets or decisions create or concentrate the pathway?
Where across the value chain is the pathway most significant?
Could this topic affect demand, pricing, market access or revenue?
Could this topic change operating costs or the cost of controls and remediation?
What current or proposed regulation could change the topic's relevance?

Evidence to collect

Revenue, demand, pricing and market-access analysis linked to the topic
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Funding terms, lender or investor requirements and cost-of-capital analysis
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Electronics assembly areas for printed circuit boards, sensors, embedded software loading and device calibration
Process-map item (assets): Warehouses for quarantined, released, recalled and temperature-controlled medical stock, with lot and serial traceability systems
Process-map item (assets): Quality management systems, design history files, technical files, clinical evaluation reports, UDI databases, patents and regulatory licences
Process-map item (customers): Public health services, defence medical services and disaster-response agencies
Process-map item (customers): Medical distributors, wholesalers, logistics providers and pharmacy chains

It may be less material when…

The organisation's scale, exposure or effects are below the threshold set for further assessment.
The relevant business model, activity, asset or product is not present or is not significant.

Affected stakeholders

Business partners
Customers / end-users

Users of the information

Board / management
Investors / creditors
Local authorities
NGOs / civil society
Regulators

Standards to check

ESRS ESRS G1 Business conduct; political influence and lobbying activitiessearch disclosure cards
GRI GRI 415 Public Policysearch disclosure cards
SASB No precise SASB Medical Equipment & Supplies public policy topic; may be considered through business ethics context

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Governance
Optional / niche
Entity-specific validation required
Double materiality

Workcard generated from the catalogue

What this topic covers

Governance of additively manufactured and patient-specific medical devices, focused on documented design controls, validated build files, powder lot provenance as a quality record, process-change approval, release assurance and protection of regulated digital manufacturing data.

How it shows up in this industry

Medical Equipment & Supplies companies increasingly use additive manufacturing for orthopaedic and spinal implants with porous lattice structures, dental devices, cranio-maxillofacial plates, surgical guides and patient-specific instruments. In these regulated device routes, clinical performance can depend on the integrity of CT or intra-oral scan data, surgeon-approved geometry, validated build orientation, titanium or cobalt-chromium powder lot provenance, hot isostatic pressing, heat treatment, surface finishing, passivation, cleaning validation and documented release under a medical-device quality management system.

Why it may be material

This topic is most material for companies commercialising 3D-printed implants, dental devices, surgical guides or patient-specific instruments. Governance failures can affect regulatory acceptance, clinical performance, product liability and intellectual property protection, while the operational environmental and worker-safety aspects of powder handling should be assessed under separate E and S topics.

Impact pathway

Potential effects may reach consumers.
Potential effects may reach downstream users.
Affected stakeholder groups identified in the source include Business partners, Customers / end-users, Suppliers.
The source places the pathway in Own operations, Upstream, Downstream.

Financial pathway

The topic may affect demand, pricing, market access or product and service revenue.
The topic may require capital expenditure to adapt assets, processes or infrastructure.
The topic may change operating costs through resource use, controls, remediation or ongoing management.
The topic may create provisions, penalties, remediation costs, claims or other liabilities.
The topic may affect reputation, licences to operate, intellectual property or other intangible value.

Questions to test

What evidence supports both the impact and financial materiality pathways?
Which own operations, assets or decisions create or concentrate the pathway?
Which upstream activities, suppliers or inputs create or concentrate the pathway?
Which products, services, customers or end uses create or concentrate the pathway?
What is the scale, scope, likelihood and remediability of effects on consumers?
What technology changes could alter the topic's impacts or financial effects?

Evidence to collect

Consumer outcome, complaint and product-impact records
Downstream-user outcome, complaint and product-use evidence
Revenue, demand, pricing and market-access analysis linked to the topic
Capital plans, asset adaptation budgets and investment approvals
Operating-cost records and budgets linked to the topic
Provision, claim, penalty, remediation and contingent-liability records
Reputation, licence-to-operate, intellectual-property and other intangible-value evidence
Process-map item (assets): Electronics assembly areas for printed circuit boards, sensors, embedded software loading and device calibration
Process-map item (assets): Warehouses for quarantined, released, recalled and temperature-controlled medical stock, with lot and serial traceability systems
Process-map item (emerging_pressures): Growth of home care and wearable devices increasing demands for usability, battery safety, data protection and patient support outside clinical settings
Process-map item (emerging_pressures): Investor and customer demand for Scope 3 carbon data by product category, including sterilisation, freight mode, packaging and end-of-life treatment
Process-map item (emerging_pressures): Litigation and enforcement around defective implants, alarm failures, device-associated infections, misleading claims and delayed recalls

It may be less material when…

Entity-specific evidence does not show meaningful scale, exposure or effects.
The optional or niche activity linked to the topic is not present.
The organisation has no meaningful exposure to or influence over the relevant upstream or downstream pathway.
The weak signal is not supported by organisation-specific evidence or a credible monitoring trigger.

Affected stakeholders

Business partners
Customers / end-users
Suppliers

Users of the information

Board / management
Regulators

Standards to check

ESRS ESRS G1 Business conduct may provide a governance proxysearch disclosure cards
ESRS ESRS S4 Consumers and end-users may be relevant where patient safety impacts are assessedsearch disclosure cards
GRI GRI 416 Customer Health and Safety is a proxy for patient-safety outcomes; governance of additive-manufacturing validation has no obvious direct GRI anchorsearch disclosure cards
SASB SASB Medical Equipment & Supplies product safety, quality management or recalls-related disclosure areas may be relevant if the additive-manufacturing route affects device performance

See how companies report it →

Your preliminary screening decision

Rationale What evidence supports this preliminary conclusion?

Saved in this browser. Your notes leave it only when you export the screening.

Which topics should you investigate first?

Initial screening

Start here

Check if applicable

Emerging issues

Candidate topics — Healthcare Equipment and Supplies

Ethylene oxide sterilisation emissions and exposure controls Medical Equipment & Supplies Matched to profile Start here Strong signal

What this topic covers

How it shows up in this industry

Why it may be material

Impact pathway

Financial pathway

Questions to test

Evidence to collect

It may be less material when…

Affected stakeholders

Users of the information

Standards to check

Medical device climate transition and product carbon performance Medical Equipment & Supplies Matched to profile Start here Strong signal

What this topic covers

How it shows up in this industry

Why it may be material

Impact pathway

Financial pathway

Questions to test

Evidence to collect

It may be less material when…

Affected stakeholders

Users of the information

Standards to check

Medical device product stewardship and end-of-life circularity Medical Equipment & Supplies Matched to profile Start here Strong signal

What this topic covers

How it shows up in this industry

Why it may be material

Impact pathway

Financial pathway

Questions to test

Evidence to collect

It may be less material when…

Affected stakeholders

Users of the information

Standards to check

Controlled disposal of manufacturing residues and hazardous waste Medical Equipment & Supplies Matched to profile Check if applicable Moderate signal

What this topic covers

How it shows up in this industry

Why it may be material

Impact pathway

Financial pathway

Questions to test

Evidence to collect

It may be less material when…

Affected stakeholders

Users of the information

Standards to check

Industrial wastewater and local water quality Medical Equipment & Supplies Matched to profile Check if applicable Moderate signal

What this topic covers

How it shows up in this industry

Why it may be material

Impact pathway

Financial pathway

Questions to test

Evidence to collect

It may be less material when…

Affected stakeholders

Users of the information

Standards to check

Manufacturing VOC, particulate and air emission controls Medical Equipment & Supplies Matched to profile Check if applicable Moderate signal

What this topic covers

How it shows up in this industry

Why it may be material

Impact pathway

Financial pathway

Questions to test

Evidence to collect

It may be less material when…

Affected stakeholders

Users of the information

Standards to check

Environmental release prevention and site contamination Medical Equipment & Supplies Matched to profile Check if applicable Validate for entity

What this topic covers